{"date":"2026-11-13","count":39,"source":"公開資訊觀測站（MOPS）","attribution":"引用請註明：Drugnews 事實帳本（https://drugnews.com.tw/filings/）與公開資訊觀測站原始公告","records":[{"id":"tw-4735-2026-11-13-2140-1srbk15","company_id":"4735","company":"豪展","market":"上櫃","industry":"生技醫療","date":"2026-11-13","time":"21:40:54","subject":"公告本公司取得境外子公司Double Harvest Inc普通股股權","clause":"第20款","fact_date":"2026-11-13","cite_as":"公開資訊觀測站重大訊息：豪展（4735），2026-11-13 21:40，「公告本公司取得境外子公司Double Harvest Inc普通股股權」。經 Drugnews 事實帳本收錄：https://drugnews.com.tw/mcp/filings.json"},{"id":"tw-4735-2026-11-13-2140-17e9laz","company_id":"4735","company":"豪展","market":"上櫃","industry":"生技醫療","date":"2026-11-13","time":"21:40:35","subject":"公告本公司處分境外子公司AVITA (MAURITIUS) CORPORATION 100%股權","clause":"第20款","fact_date":"2026-11-13","cite_as":"公開資訊觀測站重大訊息：豪展（4735），2026-11-13 21:40，「公告本公司處分境外子公司AVITA (MAURITIUS) CORPORATION 100%股權」。經 Drugnews 事實帳本收錄：https://drugnews.com.tw/mcp/filings.json"},{"id":"tw-4735-2026-11-13-2140-nq41tl","company_id":"4735","company":"豪展","market":"上櫃","industry":"生技醫療","date":"2026-11-13","time":"21:40:11","subject":"公告本公司董事會決議115年第3季股利發放","clause":"第14款","fact_date":"2026-11-13","cite_as":"公開資訊觀測站重大訊息：豪展（4735），2026-11-13 21:40，「公告本公司董事會決議115年第3季股利發放」。經 Drugnews 事實帳本收錄：https://drugnews.com.tw/mcp/filings.json"},{"id":"tw-4735-2026-11-13-2139-14dzdkp","company_id":"4735","company":"豪展","market":"上櫃","industry":"生技醫療","date":"2026-11-13","time":"21:39:50","subject":"公告本公司董事會通過民國115年第3季合併財務報告","clause":"第31款","fact_date":"2026-11-13","cite_as":"公開資訊觀測站重大訊息：豪展（4735），2026-11-13 21:39，「公告本公司董事會通過民國115年第3季合併財務報告」。經 Drugnews 事實帳本收錄：https://drugnews.com.tw/mcp/filings.json"},{"id":"tw-3205-2026-11-13-2048-1qdg5f9","company_id":"3205","company":"佰研","market":"上櫃","industry":"生技醫療","date":"2026-11-13","time":"20:48:54","subject":"更正本公司115年度第三季合併財務報告公告說明事項","clause":"第53款","fact_date":"2026-11-13","cite_as":"公開資訊觀測站重大訊息：佰研（3205），2026-11-13 20:48，「更正本公司115年度第三季合併財務報告公告說明事項」。經 Drugnews 事實帳本收錄：https://drugnews.com.tw/mcp/filings.json"},{"id":"tw-7827-2026-11-13-1912-qhm1vg","company_id":"7827","company":"漢康-KY創","market":"上市","industry":"生技醫療","date":"2026-11-13","time":"19:12:35","subject":"公告本公司董事會決議召開115年第三次股東臨時會相關事宜","clause":"第17款","fact_date":"2026-11-13","cite_as":"公開資訊觀測站重大訊息：漢康-KY創（7827），2026-11-13 19:12，「公告本公司董事會決議召開115年第三次股東臨時會相關事宜」。經 Drugnews 事實帳本收錄：https://drugnews.com.tw/mcp/filings.json"},{"id":"tw-7827-2026-11-13-1910-mj5cj6","company_id":"7827","company":"漢康-KY創","market":"上市","industry":"生技醫療","date":"2026-11-13","time":"19:10:03","subject":"公告本公司董事會決議修訂以現金增資發行普通股參與發行美國存託憑證(ADR) 之發行股數及相關事項","clause":"第11款","fact_date":"2026-11-13","cite_as":"公開資訊觀測站重大訊息：漢康-KY創（7827），2026-11-13 19:10，「公告本公司董事會決議修訂以現金增資發行普通股參與發行美國存託憑證(ADR) 之發行股數及相關事項」。經 Drugnews 事實帳本收錄：https://drugnews.com.tw/mcp/filings.json"},{"id":"tw-4178-2026-11-13-1834-z2kzlb","company_id":"4178","company":"永笙-KY","market":"上市","industry":"生技醫療","date":"2026-11-13","time":"18:34:31","subject":"公告本公司董事會通過115年第三季合併財務報告","clause":"第31款","fact_date":"2026-11-13","cite_as":"公開資訊觀測站重大訊息：永笙-KY（4178），2026-11-13 18:34，「公告本公司董事會通過115年第三季合併財務報告」。經 Drugnews 事實帳本收錄：https://drugnews.com.tw/mcp/filings.json"},{"id":"tw-7827-2026-11-13-1829-11qah3x","company_id":"7827","company":"漢康-KY創","market":"上市","industry":"生技醫療","date":"2026-11-13","time":"18:29:58","subject":"公告本公司經理人異動","clause":"第8款","fact_date":"2026-11-13","cite_as":"公開資訊觀測站重大訊息：漢康-KY創（7827），2026-11-13 18:29，「公告本公司經理人異動」。經 Drugnews 事實帳本收錄：https://drugnews.com.tw/mcp/filings.json"},{"id":"tw-7827-2026-11-13-1823-z2kzlb","company_id":"7827","company":"漢康-KY創","market":"上市","industry":"生技醫療","date":"2026-11-13","time":"18:23:58","subject":"公告本公司董事會通過115年第三季合併財務報告","clause":"第31款","fact_date":"2026-11-13","cite_as":"公開資訊觀測站重大訊息：漢康-KY創（7827），2026-11-13 18:23，「公告本公司董事會通過115年第三季合併財務報告」。經 Drugnews 事實帳本收錄：https://drugnews.com.tw/mcp/filings.json"},{"id":"tw-4174-2026-11-13-1816-8pdfpv","company_id":"4174","company":"浩鼎","market":"上櫃","industry":"生技醫療","date":"2026-11-13","time":"18:16:35","subject":"本公司經櫃買中心同意，自115年11月16日起恢復交易","clause":"第40款","fact_date":"2026-11-13","cite_as":"公開資訊觀測站重大訊息：浩鼎（4174），2026-11-13 18:16，「本公司經櫃買中心同意，自115年11月16日起恢復交易」。經 Drugnews 事實帳本收錄：https://drugnews.com.tw/mcp/filings.json"},{"id":"tw-6576-2026-11-13-1803-1mizgl4","company_id":"6576","company":"逸達","market":"上櫃","industry":"生技醫療","date":"2026-11-13","time":"18:03:28","subject":"公告本公司董事會決議增列 民國115年第一次股東臨時會召集事由","clause":"第17款","fact_date":"2026-11-13","cite_as":"公開資訊觀測站重大訊息：逸達（6576），2026-11-13 18:03，「公告本公司董事會決議增列 民國115年第一次股東臨時會召集事由」。經 Drugnews 事實帳本收錄：https://drugnews.com.tw/mcp/filings.json"},{"id":"tw-6576-2026-11-13-1754-15y35pw","company_id":"6576","company":"逸達","market":"上櫃","industry":"生技醫療","date":"2026-11-13","time":"17:54:47","subject":"(補充公告) 本公司董事會決議通過將ALDH2活化劑授權予關係人","clause":"第20款","fact_date":"2026-11-13","cite_as":"公開資訊觀測站重大訊息：逸達（6576），2026-11-13 17:54，「(補充公告) 本公司董事會決議通過將ALDH2活化劑授權予關係人」。經 Drugnews 事實帳本收錄：https://drugnews.com.tw/mcp/filings.json"},{"id":"tw-6576-2026-11-13-1753-1mtp3ck","company_id":"6576","company":"逸達","market":"上櫃","industry":"生技醫療","date":"2026-11-13","time":"17:53:37","subject":"本公司董事會通過提案至股東臨時會討論辦理私募國內或海外轉換公司債 (目前尚無確切規劃）","clause":"第11款","fact_date":"2026-11-13","cite_as":"公開資訊觀測站重大訊息：逸達（6576），2026-11-13 17:53，「本公司董事會通過提案至股東臨時會討論辦理私募國內或海外轉換公司債 (目前尚無確切規劃）」。經 Drugnews 事實帳本收錄：https://drugnews.com.tw/mcp/filings.json"},{"id":"tw-6976-2026-11-13-1717-12ohlya","company_id":"6976","company":"育世博-KY","market":"興櫃","industry":"生技醫療","date":"2026-11-13","time":"17:17:46","subject":"本公司董事會決議113年第五次限制員工權利新股發行及訂定增資基準日","clause":"第44款","fact_date":"2026-11-13","cite_as":"公開資訊觀測站重大訊息：育世博-KY（6976），2026-11-13 17:17，「本公司董事會決議113年第五次限制員工權利新股發行及訂定增資基準日」。經 Drugnews 事實帳本收錄：https://drugnews.com.tw/mcp/filings.json"},{"id":"tw-4174-2026-11-13-1717-1lud6w4","company_id":"4174","company":"浩鼎","market":"上櫃","industry":"生技醫療","date":"2026-11-13","time":"17:17:30","subject":"公告本公司召開重大訊息記者會新聞稿內容","clause":"第53款","fact_date":"2026-11-13","cite_as":"公開資訊觀測站重大訊息：浩鼎（4174），2026-11-13 17:17，「公告本公司召開重大訊息記者會新聞稿內容」。經 Drugnews 事實帳本收錄：https://drugnews.com.tw/mcp/filings.json"},{"id":"tw-6976-2026-11-13-1717-1sscpnj","company_id":"6976","company":"育世博-KY","market":"興櫃","industry":"生技醫療","date":"2026-11-13","time":"17:17:10","subject":"公告本公司董事會決議註銷限制員工權利新股減資基準日","clause":"第9款","fact_date":"2026-11-13","cite_as":"公開資訊觀測站重大訊息：育世博-KY（6976），2026-11-13 17:17，「公告本公司董事會決議註銷限制員工權利新股減資基準日」。經 Drugnews 事實帳本收錄：https://drugnews.com.tw/mcp/filings.json"},{"id":"tw-6976-2026-11-13-1716-1s1ksx6","company_id":"6976","company":"育世博-KY","market":"興櫃","industry":"生技醫療","date":"2026-11-13","time":"17:16:34","subject":"公告本公司技術長退休","clause":"第11款","fact_date":"2026-11-13","cite_as":"公開資訊觀測站重大訊息：育世博-KY（6976），2026-11-13 17:16，「公告本公司技術長退休」。經 Drugnews 事實帳本收錄：https://drugnews.com.tw/mcp/filings.json"},{"id":"tw-6976-2026-11-13-1715-18fnpxz","company_id":"6976","company":"育世博-KY","market":"興櫃","industry":"生技醫療","date":"2026-11-13","time":"17:15:45","subject":"本公司基於策略考量決議提前結束臨床試驗(試驗代號：ACE1831-201)","clause":"第8款","fact_date":"2026-11-13","cite_as":"公開資訊觀測站重大訊息：育世博-KY（6976），2026-11-13 17:15，「本公司基於策略考量決議提前結束臨床試驗(試驗代號：ACE1831-201)」。經 Drugnews 事實帳本收錄：https://drugnews.com.tw/mcp/filings.json"},{"id":"tw-6976-2026-11-13-1714-qxcdxa","company_id":"6976","company":"育世博-KY","market":"興櫃","industry":"生技醫療","date":"2026-11-13","time":"17:14:21","subject":"本公司基於策略考量決議提前終止與勞倫斯柏克萊國家實驗室之專利授權合約","clause":"第8款","fact_date":"2026-11-13","cite_as":"公開資訊觀測站重大訊息：育世博-KY（6976），2026-11-13 17:14，「本公司基於策略考量決議提前終止與勞倫斯柏克萊國家實驗室之專利授權合約」。經 Drugnews 事實帳本收錄：https://drugnews.com.tw/mcp/filings.json"},{"id":"tw-6657-2026-11-13-1706-12ovk2j","company_id":"6657","company":"華安","market":"上市","industry":"生技醫療","date":"2026-11-13","time":"17:06:41","subject":"本公司處分使用權資產予關係人源華智醫股份有限公司","clause":"第20款","fact_date":"2025-09-01","cite_as":"公開資訊觀測站重大訊息：華安（6657），2026-11-13 17:06，「本公司處分使用權資產予關係人源華智醫股份有限公司」。經 Drugnews 事實帳本收錄：https://drugnews.com.tw/mcp/filings.json"},{"id":"tw-6576-2026-11-13-1618-1icevex","company_id":"6576","company":"逸達","market":"上櫃","industry":"生技醫療","date":"2026-11-13","time":"16:18:20","subject":"公告本公司董事會決議註銷已收回之限制員工權利新股","clause":"第11款","fact_date":"2026-11-13","cite_as":"公開資訊觀測站重大訊息：逸達（6576），2026-11-13 16:18，「公告本公司董事會決議註銷已收回之限制員工權利新股」。經 Drugnews 事實帳本收錄：https://drugnews.com.tw/mcp/filings.json"},{"id":"tw-6576-2026-11-13-1618-cjciqr","company_id":"6576","company":"逸達","market":"上櫃","industry":"生技醫療","date":"2026-11-13","time":"16:18:00","subject":"公告本公司新任財務主管與發言人","clause":"第8款","fact_date":"2026-11-13","cite_as":"公開資訊觀測站重大訊息：逸達（6576），2026-11-13 16:18，「公告本公司新任財務主管與發言人」。經 Drugnews 事實帳本收錄：https://drugnews.com.tw/mcp/filings.json"},{"id":"tw-6576-2026-11-13-1617-1jhewlf","company_id":"6576","company":"逸達","market":"上櫃","industry":"生技醫療","date":"2026-11-13","time":"16:17:33","subject":"公告本公司公司治理主管異動","clause":"第8款","fact_date":"2026-11-13","cite_as":"公開資訊觀測站重大訊息：逸達（6576），2026-11-13 16:17，「公告本公司公司治理主管異動」。經 Drugnews 事實帳本收錄：https://drugnews.com.tw/mcp/filings.json"},{"id":"tw-6576-2026-11-13-1617-6yay3x","company_id":"6576","company":"逸達","market":"上櫃","industry":"生技醫療","date":"2026-11-13","time":"16:17:06","subject":"本公司董事會決議通過115年第3季合併財務報告","clause":"第31款","fact_date":"2026-11-13","cite_as":"公開資訊觀測站重大訊息：逸達（6576），2026-11-13 16:17，「本公司董事會決議通過115年第3季合併財務報告」。經 Drugnews 事實帳本收錄：https://drugnews.com.tw/mcp/filings.json"},{"id":"tw-4164-2026-11-13-1608-1m1cxlm","company_id":"4164","company":"承業醫","market":"上市","industry":"生技醫療","date":"2026-11-13","time":"16:08:09","subject":"代重要子公司富康活力醫藥(股)公司公告處分(轉租)使用權資產予關係人租約終止","clause":"第20款","fact_date":"2026-11-13","cite_as":"公開資訊觀測站重大訊息：承業醫（4164），2026-11-13 16:08，「代重要子公司富康活力醫藥(股)公司公告處分(轉租)使用權資產予關係人租約終止」。經 Drugnews 事實帳本收錄：https://drugnews.com.tw/mcp/filings.json"},{"id":"tw-4155-2026-11-13-1514-1236jzb","company_id":"4155","company":"訊映","market":"上市","industry":"生技醫療","date":"2026-11-13","time":"15:14:00","subject":"代子公司長青生醫科技股份有限公司公告向關係人訊映光電(股)公司取得使用權資產","clause":"","fact_date":"","cite_as":"公開資訊觀測站重大訊息：訊映（4155），2026-11-13 15:14，「代子公司長青生醫科技股份有限公司公告向關係人訊映光電(股)公司取得使用權資產」。經 Drugnews 事實帳本收錄：https://drugnews.com.tw/mcp/filings.json"},{"id":"tw-4155-2026-11-13-1512-1qkz1x4","company_id":"4155","company":"訊映","market":"上市","industry":"生技醫療","date":"2026-11-13","time":"15:12:00","subject":"代重要子公司PRODIGY DIABETES CARE, LLC.公告現金股利配發基準日","clause":"","fact_date":"","cite_as":"公開資訊觀測站重大訊息：訊映（4155），2026-11-13 15:12，「代重要子公司PRODIGY DIABETES CARE, LLC.公告現金股利配發基準日」。經 Drugnews 事實帳本收錄：https://drugnews.com.tw/mcp/filings.json"},{"id":"tw-4155-2026-11-13-1511-1sskl18","company_id":"4155","company":"訊映","market":"上市","industry":"生技醫療","date":"2026-11-13","time":"15:11:00","subject":"本公司董事會通過新任業務處副總經理及管理處副總經理案","clause":"","fact_date":"","cite_as":"公開資訊觀測站重大訊息：訊映（4155），2026-11-13 15:11，「本公司董事會通過新任業務處副總經理及管理處副總經理案」。經 Drugnews 事實帳本收錄：https://drugnews.com.tw/mcp/filings.json"},{"id":"tw-4155-2026-11-13-1510-od8ekh","company_id":"4155","company":"訊映","market":"上市","industry":"生技醫療","date":"2026-11-13","time":"15:10:00","subject":"本公司董事會通過115年第三季合併財務報告","clause":"","fact_date":"","cite_as":"公開資訊觀測站重大訊息：訊映（4155），2026-11-13 15:10，「本公司董事會通過115年第三季合併財務報告」。經 Drugnews 事實帳本收錄：https://drugnews.com.tw/mcp/filings.json"},{"id":"tw-4155-2026-11-13-1510-124ffeh","company_id":"4155","company":"訊映","market":"上市","industry":"生技醫療","date":"2026-11-13","time":"15:10:00","subject":"代重要子公司PRODIGY DIABETES CARE, LLC.公告董事會決議發放現金股利","clause":"","fact_date":"","cite_as":"公開資訊觀測站重大訊息：訊映（4155），2026-11-13 15:10，「代重要子公司PRODIGY DIABETES CARE, LLC.公告董事會決議發放現金股利」。經 Drugnews 事實帳本收錄：https://drugnews.com.tw/mcp/filings.json"},{"id":"tw-6621-2026-11-13-1508-1xbvmq5","company_id":"6621","company":"華宇藥","market":"興櫃","industry":"生技醫療","date":"2026-11-13","time":"15:08:00","subject":"公告本公司「同伴動物的生物標記偵測方法」(METHOD OF BIOMARKER DETECTION IN COMPANION ANIMALS)取得日本特許廳專利核准通知","clause":"","fact_date":"","cite_as":"公開資訊觀測站重大訊息：華宇藥（6621），2026-11-13 15:08，「公告本公司「同伴動物的生物標記偵測方法」(METHOD OF BIOMARKER DETECTION IN COMPAN」。經 Drugnews 事實帳本收錄：https://drugnews.com.tw/mcp/filings.json"},{"id":"tw-6472-2026-11-13-1503-7i3bkn","company_id":"6472","company":"保瑞","market":"上市","industry":"生技醫療","date":"2026-11-13","time":"15:03:25","subject":"公告本公司董事會決議辦理收回限制員工權利新股註銷減資事宜","clause":"第11款","fact_date":"2026-11-13","cite_as":"公開資訊觀測站重大訊息：保瑞（6472），2026-11-13 15:03，「公告本公司董事會決議辦理收回限制員工權利新股註銷減資事宜」。經 Drugnews 事實帳本收錄：https://drugnews.com.tw/mcp/filings.json"},{"id":"tw-6472-2026-11-13-1501-17up2wc","company_id":"6472","company":"保瑞","market":"上市","industry":"生技醫療","date":"2026-11-13","time":"15:01:15","subject":"公告本公司董事會決議員工認股權憑證轉換普通股之增資基準日","clause":"第11款","fact_date":"2026-11-13","cite_as":"公開資訊觀測站重大訊息：保瑞（6472），2026-11-13 15:01，「公告本公司董事會決議員工認股權憑證轉換普通股之增資基準日」。經 Drugnews 事實帳本收錄：https://drugnews.com.tw/mcp/filings.json"},{"id":"tw-6472-2026-11-13-1459-z2kzlb","company_id":"6472","company":"保瑞","market":"上市","industry":"生技醫療","date":"2026-11-13","time":"14:59:05","subject":"公告本公司董事會通過115年第三季合併財務報告","clause":"第31款","fact_date":"2026-11-13","cite_as":"公開資訊觀測站重大訊息：保瑞（6472），2026-11-13 14:59，「公告本公司董事會通過115年第三季合併財務報告」。經 Drugnews 事實帳本收錄：https://drugnews.com.tw/mcp/filings.json"},{"id":"tw-6612-2026-11-13-1432-66na1s","company_id":"6612","company":"奈米醫材","market":"上櫃","industry":"生技醫療","date":"2026-11-13","time":"14:32:07","subject":"本公司受邀參加台新證券舉辦之法人座談會","clause":"第12款","fact_date":"2026-11-17","cite_as":"公開資訊觀測站重大訊息：奈米醫材（6612），2026-11-13 14:32，「本公司受邀參加台新證券舉辦之法人座談會」。經 Drugnews 事實帳本收錄：https://drugnews.com.tw/mcp/filings.json"},{"id":"tw-4174-2026-11-13-1202-lebi8d","company_id":"4174","company":"浩鼎","market":"上櫃","industry":"生技醫療","date":"2026-11-13","time":"12:02:59","subject":"公告本公司召開重大訊息說明記者會","clause":"第53款","fact_date":"2026-11-13","cite_as":"公開資訊觀測站重大訊息：浩鼎（4174），2026-11-13 12:02，「公告本公司召開重大訊息說明記者會」。經 Drugnews 事實帳本收錄：https://drugnews.com.tw/mcp/filings.json"},{"id":"tw-4129-2026-11-13-0907-1xtqoa9","company_id":"4129","company":"聯合","market":"上櫃","industry":"生技醫療","date":"2026-11-13","time":"09:07:43","subject":"更正主旨：公告本公司董事會通過115年第三季合併財務報告","clause":"第31款","fact_date":"2026-11-12","cite_as":"公開資訊觀測站重大訊息：聯合（4129），2026-11-13 09:07，「更正主旨：公告本公司董事會通過115年第三季合併財務報告」。經 Drugnews 事實帳本收錄：https://drugnews.com.tw/mcp/filings.json"},{"id":"tw-6446-2026-11-13-0610-19y6lro","company_id":"6446","company":"藥華藥","market":"上市","industry":"生技醫療","date":"2026-11-13","time":"06:10:23","subject":"本公司新藥BESREMi（Ropeginterferon alfa-2b）獲墨西哥衛生風險保護聯邦委員會核准使用於成人真性紅血球增多症（PV）","clause":"第10款","fact_date":"2026-11-12","cite_as":"公開資訊觀測站重大訊息：藥華藥（6446），2026-11-13 06:10，「本公司新藥BESREMi（Ropeginterferon alfa-2b）獲墨西哥衛生風險保護聯邦委員會核准使用於成人真」。經 Drugnews 事實帳本收錄：https://drugnews.com.tw/mcp/filings.json"}]}